Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury
Cibele Rocha-Resende, … , Kory J. Lavine, Douglas L. Mann
Cibele Rocha-Resende, … , Kory J. Lavine, Douglas L. Mann
Published June 4, 2019
Citation Information: JCI Insight. 2019;4(14):e128961. https://doi.org/10.1172/jci.insight.128961.
View: Text | PDF
Research Article Cardiology Inflammation

Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury

  • Text
  • PDF
Abstract

Whereas prior studies have demonstrated an important immunomodulatory role for the neuronal cholinergic system in the heart, the role of the nonneuronal cholinergic system is not well understood. To address the immunomodulatory role of the nonneuronal cholinergic system in the heart, we used a previously validated diphtheria toxin–induced (DT-induced) cardiomyocyte ablation model (Rosa26-DTMlc2v-Cre mice). DT-injected Rosa26-DTMlc2v-Cre mice were treated with diluent or pyridostigmine bromide (PYR), a reversible cholinesterase inhibitor. PYR treatment resulted in increased survival and decreased numbers of MHC-IIloCCR2+ macrophages in DT-injected Rosa26-DTMlc2v-Cre mice compared with diluent-treated Rosa26-DTMlc2v-Cre mice. Importantly, the expression of CCL2/7 mRNA and protein was reduced in the hearts of PYR-treated mice. Backcrossing Rosa26-DTMlc2v-Cre mice with a transgenic mouse line (Chat-ChR2) that constitutively overexpresses the vesicular acetylcholine transporter (VAChT) resulted in decreased expression of Ccl2/7 mRNA and decreased numbers of CD68+ cells in DT-injured Rosa26-DTMlc2v-Cre/Chat-ChR2 mouse hearts, consistent with the pharmacologic studies with PYR. In vitro studies with cultures of LPS-stimulated peritoneal macrophages revealed a concentration-dependent reduction in CCL2 secretion following stimulation with acetylcholine, nicotine, and muscarine. To our knowledge, these findings reveal a previously unappreciated immunomodulatory role for the nonneuronal cholinergic system in regulating homeostatic responses in the heart following tissue injury.

Authors

Cibele Rocha-Resende, Carla Weinheimer, Geetika Bajpai, Luigi Adamo, Scot J. Matkovich, Joel Schilling, Philip M. Barger, Kory J. Lavine, Douglas L. Mann

×

Figure 3

PYR treatment inhibits the influx of monocytes to the heart following diphtheria toxin–mediated injury.

Options: View larger image (or click on image) Download as PowerPoint
PYR treatment inhibits the influx of monocytes to the heart following di...
(A) Representative immunofluorescence images of CD68+ cells in the hearts of diphtheria toxin–injected (DT-injected) (day 5) Rosa26-DTMlc2v-Cre (Rosa26-DT) and littermate control (LM) mice treated with PYR or diluent (PBS). Scale bar: 20 μm. (B) Group data for CD68+ staining in the hearts of DT-injected (day 5) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent (n = 10 myocardium sections/group obtained from 5 hearts per condition). (C) Group data for CD64+ macrophages/monocytes in the hearts of DT-injected (day 5) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent by flow cytometry (n = 7–12 hearts/condition). (D) Representative FACS analysis of macrophage subsets (MHC-IIhi/lo, CCR2+/–) in the hearts of DT-injected (day 5) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent. (E) Group data of macrophage subsets (MHC-IIhi/lo, CCR2+/–) in the hearts of DT-injected (day 5) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent (n = 7–12 hearts/condition). (F) Group data for circulating F4/80+Ly6Chi monocytes in DT-injected (day 3) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent (n = 5–9 mice/group). (G) Group data for CD64+ cells in the spleens of DT-injected (day 3) Rosa26-DTMlc2v-Cre and LM mice treated with PYR or diluent (n = 5–10 mice/group). *P < 0.05 in comparison with LM/PBS and LM/PYR. P values were calculated with 1-way ANOVA followed by the Tukey post hoc test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts